PULM

Pulmatrix, Inc. operates as a clinical-stage biopharmaceutical company focused on developing innovative inhaled therapies for respiratory and other diseases. Headquartered in Lexington, Massachusetts, the company utilizes its proprietary iSPERSE technology platform to create inhaled therapeutic products designed to deliver medicines more effectively to the lungs. Pulmatrix's pipeline centers on narrow-spectrum serine protease inhibitors targeting respiratory diseases, with its lead product candidate, PUR1800, being developed for treatment of alpha-1 antitrypsin deficiency-associated lung disease. The company also advances PUR1900 for cystic fibrosis and other protease-mediated pulmonary conditions. Pulmatrix's iSPERSE platform enables the production of stable, dense powder formulations that can be administered without propellants or nebulizers, potentially offering advantages in drug delivery and patient compliance. As a development-stage enterprise, the company directs its resources toward advancing clinical trials and regulatory pathways for its product candidates. Pulmatrix maintains strategic collaborations to support its research and development efforts while managing operational costs. The company faces the typical challenges of clinical-stage biotechnology firms, including the need for continued funding to support its pipeline through development and regulatory approval processes. Pulmatrix trades on the NASDAQ exchange under the ticker symbol PULM.